AnHeart Therapeutics
Dr. Bing Yan is Chief Medical Officer and Co-Founder at AnHeart Therapeutics. He was trained as a medical doctor and has more than 20 years of pharmaceutical industry experience in novel drug and vaccine development, regulatory interactions, and post-approval activities. Prior to joining AnHeart, Dr. Yan was the Global Vice-President and Head of Asia Pacific Clinical Research at Pfizer. He has deep experience across multiple therapeutic areas including neuroscience, vaccines, anti-infectives, transplant, oncology, men’s/women’s health, and metabolic disorders. He played a significant leadership role in bringing Prevnar13, Xalkori, Lyrica, Enbrel, Pristiq, Effexor, and Xyntha new drug registrations in China and Japan. Dr. Yan holds a doctorate in clinical medicine from Shanghai JiaoTong University Medical School/Ruijin Hospital and conducted his post-doc fellowship at Johns Hopkins University School of Medicine and Eastern Virginia Medical School.
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.